About Us

BRAINBERRY

Brainberry is dedicated to the research and development of effective digital therapies which will effectively impact mental well-being.

Our idea of digital healthcare came to the fore in 2016 when the company’s bootstrapping stage, lead to the idea of a therapy software highly focused on dementia symptoms to begin with.

BRAINBERRY envisions a better quality of life

The company stems from our founder’s personal experience of accompanying her grandmother through a rough journey with Parkinson’s, a decade ago.

The development of the dementiatherapy software tunnelled into the R&D process by end of 2017, leading us to start working on conducting a clinical trial with people to develop an evidence-based product aiming at treating cognitive degradation, depression, anger & anxiety; the logical reasonings which are considered to leading onset symptoms of dementia using brainwave analysis.

Now in 2020, Brainberry has evoloved into working on its advanced technology of brainwave activation leading the road to innovate solutions on mental health well-being.

After 5 years of conitnuous R&D, Brainbeery extended its technology into dementia, sleep disorder and depression. Our aim is to empower patients with the focus on mental health.

2015

BrainBerry Founded

2017

Development of COSMA Therapy Software for Dementia and Neurofeedback Headset Development for personalised therapy for dementia

2018……

Beginning of COSMA Therapy Clinical Trials Preliminary Study @University of Leicester, UK. Pilot Study @CERTH, Greece Phase II Study @Aurous, India

2020

COSMA Therapy Launch

2021

COSMA Diagnostic Development and Launch

2022

COSMA Neurofeedback Therapeutic System with Class IIB medical device Status

Our Vision

BrainBerry through continued research, supported via our unique technology, aims to lead non-pharmocoligcal therapy for mental health realated issues.  Our goal is develop a digital healthcare ecosystem to empower and provide better heath facilties on the mental forefront.

Our Mission

Is simple, to help as many people as we can to manage, alleviate and continue to lead fulfilling lives whilst dealing with mental health issues.  By collaborating with other health professionals and experts in the field  psychology and other neurodegenerative diseases; we hope to develop therapeutic and early diagnostic solution into a world leading digital therapy which can help millions of people continue to better and sound lives.

Meet the Management

KARTHEKA BOJAN

KARTHEKA BOJAN

CEO

Miss Kartheka Bojan, Founder & CEO of Cerebrum Matter Ltd, a digital healthcare
Miss Kartheka Bojan, Founder & CEO of Cerebrum Matter Ltd, a digital healthcare start-up working on early dementia. She holds an MSc in Biomedical Engineering from the University of Nottingham. After working at IBM India, she spent 5 years in the UK developing medical devices. She has an entrepreneurial spirit and a Visionary.

In her role as Chief Medical Engineer at her previous employment, she designed a Nanotechnology-based Non-Invasive Continuous Glucose Monitoring Device. She is the author of pending patents in EEG technology for Alzheimer’s & a Glucose Monitoring device and has also published work on Design of Biosensors with Gold Nanoparticles.

The idea of creating Cerebrum Matter stems from her personal experience of accompanying her grandmother through a rough journey with Parkinson’s, a decade ago. Her vision to treat early onset dementia through digital therapy has been transformed into Cerebrum Matter’s mission to reduce the prevalence of disabling symptoms for people living with dementia.

PROF.Elizabeta Mukaetova-Ladinska

PROF.Elizabeta Mukaetova-Ladinska

CLINICAL ADVISOR

Prof. Mukaetova-Ladinska is chairman of Old Age Psychiatry, University of Leicester
Prof. Mukaetova-Ladinska is chairman of Old Age Psychiatry, University of Leicester, and clinician at Leicestershire Partnership Trust (LPT). She is the clinical advisor of Cerebrum Matter Ltd. She is the clinical lead for validating the CM’s COSMA Software in collaboration with University of Leicester. Her areas of academic interest include developing biomarkers with high sensitivity and specificity to detect various forms of dementia and their implementation in the routine clinical setting to monitor the progression of the disease and treatment.

Dr Elizabeta Mukaetova-Ladinska is the lead investigator on an Alzheimer’s Society-funded study, entitled ‘Blood Markers in Dementia Study’. The potential outcome would be to develop an inexpensive yet accurate test that could differentiate between Alzheimer’s disease and other forms of dementia, such as dementia with Lewy bodies and vascular dementia.

Robert Hehakaya

Robert Hehakaya

Business Development Advisor

As a seasoned executive with over 25 years of international industry experience
As a seasoned executive with over 25 years of international industry experience, Robert has developed his expertise in a variety of roles ranging from consulting to operational management with an emphasis on strategy & transformation, sales & marketing, mergers & acquisitions, innovation and operational excellence.
 
After a global tenure at IBM he has been involved in a number of start-ups and innovation programs, The emerging Blockchain technology, AI & Robotica have caught his interest as the next game changers in building sustainable businesses with societal impact.
ADNAN ASHFAQ

ADNAN ASHFAQ

REGULATORY DIRECTOR

Adnan is the Quality, Regulatory & Validation Specialist with over 19 years of exp
Adnan is the Quality, Regulatory & Validation Specialist with over 19 years of experience in Medical Device, Biotech and Pharmaceutical industries. Adnan’s validation experience includes, Building facilities, packaging, bottling, labelling, software, water, utilities, equipment, protocol preparation, execution, man management, validation plan, policy write ups, contractor management full facility validation, training roll out in several companies.

His expertise is more towards Medical Device regulations and Pharma Industry. He is well updated with all the MDR and new regulatory policies both in Europe and USA. Adnan is responsible for all the regulatory pathway and direction of CM’s all products.

Ramana Tadepalli

Ramana Tadepalli

Strategic Advisor

Ramana is the Founder and President of California USA based 3S Ventures;
Ramana is the Founder and President of California USA based 3S Ventures; a Venture Capital and business consulting company with expertise in Medical Technologies, Biotech, Pharma, Precision Medicine, Artificial Intelligence (AI) and Blockchain in healthcare and Infrastructure.

Ramana has access to experts and senior leaders in the industry in USA, Europe, Middle East, India and Latin America. Many of these experts are formal consulting partners of 3S Ventures.

Ramana is a partner at Bridege4Bio, a California based consulting company that is involved in product development and global commercialization of Life Science products. Ramana is advisor and associate at One Rock Capital Partners, Ramana is also associated with Shoreview Capital, a St.Paul/ Minneapolis USA based Private Equity Fund and advices on Healthcare acquisitions.